Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Cancer Therapies02:49

Cancer Therapies

8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative Analysis of Ultra-Low Versus Hydrogel Growing Conditions for Patient-Derived Glioma Organoids.

Frontiers in bioscience (Landmark edition)·2026
Same author

Critical Role of Molecular-Based Stratification in Low-Risk Myelodysplastic Syndrome with Direct Progression to Acute Myeloid Leukemia: A Case Report.

International journal of molecular sciences·2026
Same author

Toll-like Receptor 7/8 Agonists Exert Antitumor Effect in a Mouse Melanoma Model.

Medicina (Kaunas, Lithuania)·2026
Same author

Monitoring SARS-CoV-2 Dissemination in Wastewater and Virus Isolation in Cell Cultures: An Integrated Approach for Pathogen Detection and Surveillance.

Journal of cellular and molecular medicine·2025
Same author

The Impact of the Microbiota on the Immune Response Modulation in Colorectal Cancer.

Biomolecules·2025
Same author

High-Resolution Genotyping of HLA Alleles and Association with Genetic Background of Virological Response in Chronic Hepatitis B.

Clinical laboratory·2025

Related Experiment Video

Updated: May 6, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

144

Anti-cancer Therapies in High Grade Gliomas.

Cristiana Pistol Tanase1, Ana-Maria Enciu, Simona Mihai

  • 1Victor Babes National Institute of Pathology, Department of Biochemistry-Proteomics, no 99-101 Splaiul Inde-pendentei, 050096 sect 5 Bucharest, Romania;

Current Proteomics
|November 15, 2013
PubMed
Summary
This summary is machine-generated.

High grade gliomas are aggressive brain cancers with poor survival. Research focuses on combination therapies targeting molecular pathways and cancer stem cells for better glioblastoma treatment.

Keywords:
Antiangiogenic therapyPI-3K.cancer stem cellsgliomamicroRNApersonalized medicine

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Related Experiment Videos

Last Updated: May 6, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

144
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

19.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

29.3K

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Cancer Research

Background:

  • High grade gliomas, including glioblastoma, are aggressive human cancers with limited treatment options and poor median survival rates (1-2 years for grade IV).
  • Current treatment strategies for glioblastoma face significant therapeutic challenges, necessitating novel approaches.
  • Combination therapy targeting multiple molecular pathways is an emerging and promising research area.

Purpose of the Study:

  • To provide an updated review of current molecular therapy targets for high grade gliomas.
  • To explore the potential of proteomic signatures for diagnosing and personalizing glioblastoma treatment.
  • To assess the current status of personalized medicine in brain tumor treatment.

Main Methods:

  • Literature review of current molecular therapy targets in high grade glioma.
  • Analysis of research on angiogenic signals, tyrosine kinase receptors, nodal signaling proteins, and cancer stem cell-related approaches.
  • Discussion of the role of proteomic signatures in personalized medicine for glioblastoma.

Main Results:

  • Identified key molecular targets including angiogenic signals, tyrosine kinase receptors, nodal signaling proteins, and cancer stem cells.
  • Highlighted the potential of simultaneous proteomic signature identification for creating diagnostic and personalized treatment biomarker panels.
  • Acknowledged the early stage of personalized medicine application in brain tumors despite successes in other cancers.

Conclusions:

  • Molecularly targeted combination therapies represent a critical area of research for improving high grade glioma outcomes.
  • Proteomic signatures offer a promising avenue for developing biomarkers for glioblastoma diagnosis and personalized treatment strategies.
  • Advancing personalized medicine is crucial for enhancing the clinical care of brain tumor patients.